ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Pharmacoepidemiology
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1628347
A Comprehensive Analysis of Adverse Drug Reactions in 2020-2023: Case Studies
Provisionally accepted
- First Affiliated Hospital of Jilin University, Changchun, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Adverse drug reactions (ADRs) have posed significant threats to patient safety and could potentially result in adverse clinical outcomes. In this study, we analyzed ADRs data reported by a large hospital spanning from 2020 to 2023, with a particular focus on identifying demographic and clinical factors associated with severe ADRs. The dataset encompassed 5,644 cases, incorporating variables such as patient age, gender, smoking and drinking history, allergies, medication type, and administration route.Among these ， 408 cases of severe ADRs underwent detailed examination.Additionally, the study delved into the correlation between adverse drug reactions symptoms (ADRS) and various drug types.According to research statistics, individuals in the middle-aged group (46-65 years) exhibited the highest proportion of severe ADRs at 36.77%. Females were significantly more affected than males, accounting for 66.67% of severe ADRs.Anti-tumor drugs emerged as the primary cause of severe ADRs, responsible for 52.70% of such incidents. Compared with other administration methods, intravenous injection was more prone to causing severe ADRs, with a likelihood of 53.92%. Furthermore, the blood system was identified as the ADRS where severe ADRs occurred at a significantly higher rate than other parts of the body, at 53.19%.Correlation analysis reveals a strong association between medication type and factors such as patient age, administration route, and ADRS. Notably, ADRS was also strongly linked to drug type, gender, and age. These findings collectively highlight the critical need for personalized treatment plans and targeted monitoring. Particular attention should be directed towards high-risk groups, such as middle-aged females and patients undergoing anti-tumor therapies. By doing so, it is possible to enhance drug safety and minimize the occurrence of severe ADRs.
Keywords: adverse drug reactions, Severe adverse drug reactions, Clinical factors, personalized treatment, Anti-tumor drug
Received: 15 May 2025; Accepted: 15 Sep 2025.
Copyright: © 2025 Zhai, Yan, Zhang, Yan, Ma and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Jinghui Zhai, zhaijh@jlu.edu.cn
Sixi Zhang, sixi@jlu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.